anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a base material for cosmetics, high in pH stability, stable, when added to the cosmetics, capable of smoothing skins, and having an action for protecting hair by using a specific N-carboxyacylchitosan. SOLUTION: This base material for cosmetics contains an N- carboxyacylchitosan having an N-carboxyacylation degree of >=80%. The N- carboxyacylchitosan is obtained by N-carboxyacylating the amino group (NH2 ) of chitosan obtained by wholly or partially deacylating the N-acyl groups of chitin. The N-carboxyacylchitosan may be combined with collagen, a polyhydric alcohol or a cationized cellulose. The N-carboxyacylchitosan is preferably N- succinylcitosan. Examples of cosmetics to be compounded with the base material include skin lotions, milky lotions, creams, packs, foundations, lip sticks and shampoos.
Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
The invention relates to the technical field of external medicines, and discloses a traditional Chinese medicine analgesic patch capable of effectively relieving vein puncture pain, which consists of a transdermal patch and a traditional Chinese medicine ointment laid on the transdermal patch, wherein the traditional Chinese medicine ointment comprises, by weight, 60g of erythrina bark, 60g of garden balsam stem, 60g of radix clematidis, 20g of prepared radix aconiti kusnezoffii, 20g of prepared radix aconiti, 20g of pepper, 60g of medicinal cyathula root, 40g of suberect spatholobus stem, 12g of liquorice, 40g of Chinese angelica and 20g of loofah sponge. The invention has the effects of warming channels, dispelling cold, eliminating dampness, dredging collaterals, clearing heat and detoxicating. Herba speranskiae tuberculatae has antiinflammatory, antibacterial, and hemostatic effects, and radix Clematidis has effects of dispelling pathogenic wind, removing dampness, dredging collaterals, relieving pain, tranquilizing, and relieving inflammation. Caulis Spatholobi can relieve inflammatory pain, drug pain and physical pain. The prepared radix Aconiti has antiinflammatory, analgesic, and immunoregulatory effects; the radix Aconiti Kusnezoffii Preparata has antiinflammatory, analgesic, and immunoregulatory effects. While licorice and pricklyash have analgesic and bactericidal effects. Radix Cyathulae and radix Angelicae sinensis have effects of promoting blood circulation, removing blood stasis, dredging collaterals and relieving pain.
BACKGROUND AND OBJECTIVES: Ocedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and efficacy in clinical trials in patients with uncontrolled hypertension and stage 3b/4 chronic kidney disease. The aim of this study was to assess the pharmacokinetics, safety, and tolerability of ocedurenone in individuals with moderate hepatic impairment.
METHODS: This study was an open-label, nonrandomized, multi-center study investigating the pharmacokinetics, safety, and tolerability of a single dose of 0.5 mg ocedurenone administered orally in male and female subjects with moderate hepatic impairment (Child-Pugh B, score 7-9) compared with subjects with normal hepatic function. Serial blood samples were obtained from predose through 264 h postdose for analysis of ocedurenone concentrations using a validated liquid chromatography-tandem mass spectrometry method. Free ocedurenone concentrations in plasma were determined ex vivo using equilibrium dialysis.
RESULTS: Following a single oral dose of 0.5 mg ocedurenone administered to subjects with moderate hepatic impairment and subjects with normal hepatic function, ocedurenone was steadily absorbed with median time to peak drug concentration (Tmax) values of 4 and 3 h, respectively. After reaching maximum plasma concentration (Cmax), the disposition of ocedurenone appeared to be biphasic. The geometric mean t1/2 values for the moderate hepatic impairment group and normal hepatic function group were 75.6 and 65.7 h, respectively. Ocedurenone systemic exposure, as assessed by area under the plasma concentration-time curve (AUC) was 23.5-26.6% lower in subjects with moderate hepatic impairment versus subjects with normal hepatic function, whereas Cmax was 41.2% lower. Ocedurenone was determined to be > 99.7% bound to total protein in plasma. Hepatic impairment appeared not to change plasma protein binding or the unbound free fraction. Ocedurenone was safe and well-tolerated in all participants.
CONCLUSIONS: Considering the long half-life of ocedurenone and previously completed clinical studies using 0.25 mg and 0.5 mg doses demonstrating efficacy and safety, the observed decreases in AUC and Cmax do not warrant a dose adjustment in patients with moderate hepatic impairment. A single 0.5 mg dose of ocedurenone was safe and well-tolerated when administered to subjects with moderate hepatic impairment and subjects with normal hepatic function. CLINICAL TRIAL IDENTIFIER ( WWW.
CLINICALTRIALS: GOV ): NCT04534699.
The rehabilitation of paretic stroke patients uses a wide range of intervention programs to improve the function of impaired upper limb. A new rehabilitative approach, called action observation therapy (AOT) is based on the discovery of mirror neurons and has been used to improve the motor functions of adult stroke patients and children with cerebral palsy. Recently, virtual reality (VR) has provided the potential to increase the frequency and effectiveness of rehabilitation treatment by offering challenging and motivating tasks. The purpose of the present project is to design a randomized controlled trial (RCT) to evaluate whether action observation (AO) added to standard VR (AO+VR) is effective in improving upper limb function in patients with stroke, compared with an action observation therapy alone.

Non-probability sampling technique will be used. After signing the consent form, the participant who met the inclusion criteria will be allocated to this study. Lottery Method will be used for the randomization of subjects in two groups. For the blindness of the accessor, the concealment process (Closed Envelope Method) will be maintained. Group A (will be given Action Observation Therapy only), During each training session, participants will be asked to observe a specific object-directed daily action presented on a computer screen, and afterward they will perform what they have observed. Group B (will be given Action Observation Therapy combined with Virtual Reality), the participant will sit in the center of the set zone and will be assisted to wear the VR glasses. After the participant will confirm that the sight and sound is clear and comfortable, the tasks will be done using virtual reality videos. Data will be collected at baseline and after 6 weeks using Box and Block Test (Measures unilateral gross manual dexterity), Timed Test (To check the time duration for each task), Modified Ashworth Scale (To assess spasticity), Rankin Scale (To categorize severity of symptoms) and Fugl-Meyer Assessment for Upper Extremity (FMA-UE): to assess motor functioning, balance, sensation and joint functioning. All participants will receive 18 sessions of intervention for 60 min/day, 3 days/week for 6 weeks.
AIM: To explore the risk of major adverse cardiovascular events (MACE) associated with exposure to bexagliflozin.
METHODS: The analysis included 4090 participants with type 2 diabetes (T2D) enrolled in nine phase 2 and 3 double-blind randomized controlled trials. All potential MACE were adjudicated by a blinded committee. The primary endpoint for the meta-analysis was the hazard ratio (HR) for the time to first occurrence of non-fatal stroke, non-fatal myocardial infarction (MI), cardiovascular (CV) death or hospitalization for unstable angina (MACE+), tested for non-inferiority to a ratio of 1.8. The secondary endpoints were time to first occurrence of (i) non-fatal stroke, non-fatal MI or CV death (MACE), tested for non-inferiority to a ratio of 1.3; and (ii) CV death or hospitalization for heart failure, tested for superiority.
RESULTS: The HR for the primary endpoint of MACE+ was 0.80 (95% confidence interval [CI] 0.58, 1.09), which fulfilled the non-inferiority objective with a P value of less than 0.0001. Non-inferiority for the first key secondary endpoint of MACE was also shown (HR = 0.82; 95% CI 0.59, 1.13; P = 0.0023). Superiority for time to CV death or first hospitalization for heart failure was not shown.
CONCLUSIONS: Bexagliflozin did not increase the risk of MACE in participants with T2D when compared with placebo or active control. Both the preapproval and postapproval thresholds for CV safety were met and bexagliflozin has been approved by the US Food and Drug Administration.
BACKGROUND: Adolescent idiopathic scoliosis (AIS), the predominant genetic-influenced scoliosis, results in spinal deformities without vertebral malformations. However, the molecular aetiology of AIS remains unclear.
METHODS: Using genome/exome sequencing, we studied 368 patients with severe AIS (Cobb angle >40°) and 3794 controls from a Han Chinese cohort. We performed gene-based and pathway-based weighted rare variant association tests to assess the mutational burden of genes and established biological pathways. Differential expression analysis of muscle tissues from 14 patients with AIS and 15 controls was served for validation.
RESULTS: SLC16A8, a lactate transporter linked to retinal glucose metabolism, was identified as a novel severe AIS-associated gene (p=3.08E-06, false discovery rate=0.009). Most AIS cases with deleterious SLC16A8 variants demonstrated early onset high myopia preceding scoliosis. Pathway-based burden test also revealed a significant enrichment in multiple carbohydrate metabolism pathways, especially galactose metabolism. Patients with deleterious variants in these genes demonstrated a significantly larger spinal curve. Genes related to catabolic processes and nutrient response showed divergent expression between AIS cases and controls, reinforcing our genomic findings.
CONCLUSION: This study uncovers the pivotal role of genetic variants in carbohydrate metabolism in the development of AIS, unveiling new insights into its aetiology and potential treatment.
The present invention provides a composition in which solid lipids such as ceramides are prevented from crystallizing so as to be stably emulsified and dispersed as particles. This dispersion of lipid particles comprises components (A) to (E) and has a pH of 3.5-8.0, wherein the amount of heat required for melting the lipid particles in a temperature range of 45-80 DEG C is not more than 0.30 J/g, and the average particle size of the lipid particles is less than 200 nm. (A) At least one selected from sterols and derivatives thereof. (B) A lipid that is either solid or semisolid at 25 DEG C, but excluding component (A). (C) An anionic surfactant. (D) A water-soluble solvent. (E) Water.
Aviane (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy.

Limitations of use: The efficacy of Aviane (levonorgestrel and ethinyl estradiol tablets) in women with a body mass index (BMI) of > 35 kg/m2 has not been adequately evaluated.

In a clinical trial with Aviane (levonorgestrel and ethinyl estradiol tablets), 1,477 subjects had 7,720 cycles of use and a total of 5 pregnancies were reported. This represents an overall pregnancy rate of 0.84 per 100 woman-years. This rate includes patients who did not take the drug correctly. One or more pills were missed during 1,479 (18.8%) of the 7,870 cycles; thus all tablets were taken during 6,391 (81.2%) of the 7,870 cycles. Of the total 7,870 cycles, a total of 150 cycles were excluded from the calculation of the Pearl index due to the use of backup contraception and/or missing 3 or more consecutive pills.

The mean BMI of the study population was 24 kg/m2. Females with a BMI greater than 30 kg/m2 accounted for 12.1% (n=179) of the study population. Females with a BMI over 35 kg/m2 accounted for 4.3% (n=63) of the study population.
The invention relates to the field of health-care otter meat balls, in particular to a health-care otter meat ball which can prevent and cure hyperlipemia. The health-care otter meat ball is characterized by comprising the following raw materials, by weight part, of 100 parts of otter meat, 2-5 parts of salt, 3-6 parts of sugar, 5-10 parts of egg white, 0.1-0.2 part of sodium bicarbonate, 0.5 part of ground pepper, 15-25 parts of starch and 10-25 parts of pimpinella diversifolia traditional Chinese medicine micro powder. The pimpinella diversifolia traditional Chinese medicine micro powder is manufactured by pimpinella diversifolia, honeysuckle, kapok and Chinese yam according to the weight part ratio of 10:5-8:5-8:5-10. The pimpinella diversifolia traditional Chinese medicine micro powder is fresh, sweet and mellow in taste, so that the taste of the otter meat ball is improved, and the health-care function of the otter meat ball is achieved. The honeysuckle, the Chinese yam and the like are used for conditioning the balance of the heart, the liver, the spleen, the lungs and the kidneys of the human body, regulating Qi, strengthening the spleen, removing thirst, dispersing blood stasis and removing turbid. The pimpinella diversifolia is used for activating blood and promoting menstruation to achieve the purpose of reducing blood fat. The otter meat ball is suitable for preventing and curing hyperlipemia and can achieve auxiliary food health care.
PCT No. PCT/EP96/02736 Sec. 371 Date Jan. 7, 1998 Sec. 102(e) Date Jan. 7, 1998 PCT Filed Jun. 24, 1996 PCT Pub. No. WO97/02812 PCT Pub. Date Jan. 30, 1997A layered tablet for the controlled release of active substances in a liquid medium comprising at least one active substance-containing, layered matrix with contact surfaces to the liquid medium which are at least partially provided with a cover layer delaying or preventing the active substance release, is characterized by the fact that the cover layer is at least one additional layer lying with thickness gradients on contact surfaces of the layered, prefabricated matrix, or that the matrix is at least one additional layer lying with thickness gradients on contact surfaces of the layered, prefabricated cover layer, which additional layer is applied by pressing powdery or granular material on the layered, prefabricated matrix or on the layered, prefabricated cover layer.
Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
This is a multicenter trial to be conducted at approximately 60 sites among 6-8 northern hemisphere countries in North America and Central Europe. Sufficient patients will be randomized in order to recruit 150 subjects who are laboratory confirmed for human rhinovirus (HRV) infection. Depending on HRV PCR positivity rates, it is expected that randomization of 250-480 subjects will be required to achieve this number of subjects with HRV infection.

Appropriate asthma subjects will be screened up to 180 days prior to presentation at the study site with symptoms of presumed HRV infection for potential study inclusion on Study Day 1. The study drug treatment period has a duration of 7 days, beginning on Study Day 1. Follow-up study visits to the clinic occur on Study Days 3, 5, 7, 14, 21, and 28 with a telephonic final safety follow-up visit conducted on Study Day 35. Thus, depending on the duration of the screening period, a subject's duration of participation can be estimated to last from approximately 37 days up to 215 days.
This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
Distal radius fracture (DRF) is one of the most frequent injuries in the upper limb, corresponding to 1/6 of the total fractures of the body. It appears mostly in \>50 years old women (due to osteoporosis and menopause) but it is also frequent in middle age men as a consequence of a big trauma during sport activities or working. This injury can be treated conservative of surgically, but regardless of the treatment, it always has a period of immobilization between 3 and 6 weeks.

The term "proprioception" was firstly described by Sherrington in 1906 as "perception" of body position and movement. The presence and quantity of mechanoreceptors in the joint determine its proprioceptive capacity. In the 1990s, the presence of mechanoreceptors on the wrist was described, and subsequent studies allowed us to determine that the dorsal and ulnar ligaments of the wrist have a rich innervation of mechanoreceptors. With these findings, we can hypothesize various clinical applications, both for working on wrist proprioception in the early stages of proprioceptive reeducation without risking tissue damage and for neuromuscular work after fracture consolidation, with the goal of regaining fluid and balanced movement. Previous studies on the ankle, knee, and shoulder have shown that the implementation of a proprioceptive program in the rehabilitation process can improve traumatic instability and pain. Given that the wrist shares similarities with these joints in terms of proprioceptive innervation, we can hypothesize that a specific proprioceptive exercise program for the wrist may be beneficial in the recovery after a wrist fracture.
Methotrexate is a dihydrofolate reductase inhibitor with the chemical name of N-[4-[[(2,4-diamino-6-pteridinyl) methyl]methylamino]benzoyl]-L-glutamic acid. The molecular weight is 454.45 g/mol and the molecular formula is C 20H 22N 8O 5. The structural formula is: 

Methotrexate is practically insoluble in water. Therefore, the pH of the methotrexate solution is adjusted to approximately 8.5 with sodium hydroxide in Water for Injection to produce Methotrexate Injection. 

Methotrexate Injection for intravenous use is supplied as clear orange-yellow, sterile, preservative-free solution in clear glass single-dose vial sealed with gray rubber stopper and yellow aluminum flip-off seal. Each 100 mg/mL, 50 mL vial contains 5 grams methotrexate and the following inactive ingredient: sodium hydroxide to adjust the pH to approximately 8.5.
PURPOSE:To obtain a solid powder cosmetic having high strength of packed material, excellent impact strength, good adhesivity to skin, improved oil repellence and durability of make-up, comprising a pigment as a main component by solidifying the pigment, etc., with a small amount of a liquid oil. CONSTITUTION:70-94.9wt.% pigment (e.g. sericite) for cosmetic, 5-25wt.% oil agent (e.g. squalane or wax) for cosmetic and 0.1-5wt.% waxy fluorine-containing polymer are contained as essential components. The components are mixed with other components usually used for cosmetic and prepared by a conventional procedure to give the objective substance. The prepared substance is applicable as face powder, body powder, powder foundation, cheek rouge, eye shadow, etc. A copolymer of a long-chain alkyl (meth)acrylate and (meth)acrylate containing a fluorinated alkyl group bond is preferable as the waxy fluorine- containing polymer.
Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Agents for inducing early, long-lasting and increased immunity consist of suboptimal doses of antigen and sulphate esters of polymers, pref. dextran sulphate, polyvinyl sulphate, pentosan sulphate, laevan sulphate, heparin, chondroitin sulphuric acid or hyaluronic acid. The sulphate dosage is pref. 0.05-200 mg/kg. body wt. The agents can be used as vaccines, to induce antibody formation in hosts or in tissue cultures, or to produce antisera for immunological determinations. The sulphate increases the antibody titre and thus reduces the antigen dose, thus reducing side effects due to high antigen doses. The sulphates increase the gamma-globulin fraction in serum and can be used to increase specific and non-specific resistance to bacterial and viral infections.
Intervention participants will be asked to download the ARTEMIS app in the Apple or Google Play app stores. The app will comprise of daily self-weighing, daily weight-recording, daily action-planning, and weekly reports and reflection. Daily weight loss action plans will predominantly relate to diet, physical activity and sleep, and comprise of eight categories, to be chosen by participants and rotated on a weekly basis, each with 5-10 actions, to be chosen by participants and rotated on a daily basis. Participants can explore and engage in all of these actions for as long as they wish within the 26-weeks of the intervention but will be recommended to continue within the 'active exploratory phase' of the intervention for at least four weeks, before moving to a 'maintenance phase', where participants continue with the actions which worked best for them in the 'active exploratory phase'.
BACKGROUND Orbital abscess is a severe infectious condition of the eye that can result in significant complications, including vision loss or fatality. Timely and accurate diagnosis and treatment of this condition are crucial. CASE REPORT A 45-year-old man with exophthalmos, diplopia, and decreased vision was admitted to our hospital. He had a history of chronic sinusitis. Ultrasonography showed a dark fluid area above the superior rectus muscle of the right eye, measuring approximately 5.7 ml. Orbital MRI revealed short T1 and long T2 signal shadows outside the upper muscle cone of the right orbit, with a size of about 13.2 ml. The right eyeball was compressed and moved forward, and the superior rectus muscle was also compressed. Long T2 signal shadows were observed in the right frontal sinus, maxillary sinus, and bilateral ethmoid sinuses, leading to a diagnosis of orbital subperiosteal abscess and sinusitis. We performed a fine-needle puncture and injection of antibiotics into the abscess cavity using a 5-ml syringe under the guidance of B-ultrasound. On the 7th day after surgery, the patient showed clinical improvement with decreased symptoms. His visual acuity improved from 20/40 to 20/20, and diplopia resolved. His sinusitis was treated with medication, and no recurrence of ocular symptoms was observed during the 3-year follow-up. CONCLUSIONS This report highlights the use of ultrasound-guided fine-needle puncture and injection of antibiotics into the abscess cavity for the treatment of an upper-quadrant orbital subperiosteal abscess. Timely surgical drainage and effective antibiotic therapy can help reduce the complications associated with orbital abscesses.